Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence

Background & Aims: Atezolizumab plus bevacizumab (A+B) is a standard-of-care treatment in unresectable hepatocellular carcinoma (uHCC). Verification of its effectiveness outside clinical trials is an area of unmet need, especially in estimating long-term survival outcomes. Methods: We conducted...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Giulia Francesca Manfredi, Claudia Angela Maria Fulgenzi, Ciro Celsa, Bernardo Stefanini, Antonio D'Alessio, Matthias Pinter, Bernhard Scheiner, Nichola Awosika, Leonardo Brunetti, Pasquale Lombardi, Charles Latchford, Pei-Chang Lee, Yi-Hsiang Huang, Chun-Yen Lin, Andrea Dalbeni, Arndt Vogel, Peter R. Galle, Masatoshi Kudo, Lorenza Rimassa, Hong Jae Chon, Giuseppe Cabibbo, Fabio Piscaglia, Calogero Cammà, Anjana Pillai, Mario Pirisi, Amit G. Singal, David J. Pinato
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Elsevier 2025-08-01
סדרה:	JHEP Reports
נושאים:	HCC Immunotherapy RWE Survival Child–Pugh
גישה מקוונת:	http://www.sciencedirect.com/science/article/pii/S2589555925001089
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!